FDA reviews continue for now

Share this article:

Banked user fees are keeping the FDA review process humming for now, reports MedPage Today, which notes that the agency approved the prescription hot flashes medication Duavee Thursday and plans to hold its advisory committee meeting for Medtronic devices this week. This in addition to green-lighting an IV nutritional treatment called Clinolipid on Thursday.

The omega-three/omega-six fatty acid blend was granted priority review to alleviate a drug shortage. MedPage Today notes that although user fees fund the regulator's review processes, they only cover around two-thirds of the cost, putting future reviews in limbo under the shutdown. As noted last week, more than half of the non-furloughed FDA employees are funded by user fees, but only 55% of the agency's staff is allowed to work until the shutdown is resolved.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.